Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Britain Courts Anthropic Amid US Defense Department Dispute 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
DUBLIN, Ireland, Sept. 06, 2016 -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that the company will present at the Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on September 12, 2016 in New York City, NY.
The conference presentation, which will include an update of Horizon’s business, will be webcast live and may be accessed by visiting Horizon's investor relations section of the website at http://ir.horizon-pharma.com. A replay of the webcast will be available for the event.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets nine medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts: Investors: John Thomas Executive Vice President, Strategy and Investor Relations [email protected] Tina Ventura Vice President, Investor Relations [email protected] U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications [email protected] Ireland Media: Ray Gordon Gordon MRM [email protected]
